<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
It may be much ado about nothing, but Biogen Inc. ( BIIB , Financial) investors can’t help but be a bit nervous that the U.S. Congress has asked for information from the Food and Drug Administration concerning the agency’s accelerated approval of the Cambridge, Massachusetts-based biotech’s new Alzheimer’s drug, Aduhelm. Following approval, the FDA came under scathing criticism from some scientists and staff, who questioned the treatment’s effectiveness, mounting further pressure on the agency that has come under fire for clearing the drug.
...read full article on GuruFocus
